94 related articles for article (PubMed ID: 21173337)
1. Regional squamous cell carcinomas following systemic sorafenib therapy and isolated limb infusion for regionally advanced metastatic melanoma of the limb.
Raymond AK; Puri PK; Selim MA; Tyler DS; Nelson KC
Arch Dermatol; 2010 Dec; 146(12):1438-9. PubMed ID: 21173337
[No Abstract] [Full Text] [Related]
2. Keratoacanthomas and squamous cell carcinomas in patients receiving sorafenib.
Arnault JP; Wechsler J; Escudier B; Spatz A; Tomasic G; Sibaud V; Aractingi S; Grange JD; Poirier-Colame V; Malka D; Soria JC; Mateus C; Robert C
J Clin Oncol; 2009 Aug; 27(23):e59-61. PubMed ID: 19597016
[No Abstract] [Full Text] [Related]
3. Eruptive squamous cell carcinomas with keratoacanthoma-like features in a patient treated with sorafenib.
Lynch MC; Straub R; Adams DR
J Drugs Dermatol; 2011 Mar; 10(3):308-10. PubMed ID: 21369650
[TBL] [Abstract][Full Text] [Related]
4. Does basal cell carcinoma belong to the spectrum of sorafenib-induced epithelial skin cancers?
Degen A; Satzger I; Voelker B; Kapp A; Hauschild A; Gutzmer R
Dermatology; 2010; 221(3):193-6. PubMed ID: 20720388
[TBL] [Abstract][Full Text] [Related]
5. Metastatic melanoma: scientific rationale for sorafenib treatment and clinical results.
Egberts F; Kahler KC; Livingstone E; Hauschild A
Onkologie; 2008 Jul; 31(7):398-403. PubMed ID: 18596389
[TBL] [Abstract][Full Text] [Related]
6. [Clinical studies with sorafenib (Nexavar) in metastatic melanoma].
Hauschild A
J Dtsch Dermatol Ges; 2007 Apr; 5(4):345. PubMed ID: 17376105
[No Abstract] [Full Text] [Related]
7. Sorafenib: delivering a targeted drug to the right targets.
Flaherty KT
Expert Rev Anticancer Ther; 2007 May; 7(5):617-26. PubMed ID: 17492926
[TBL] [Abstract][Full Text] [Related]
8. The histologic spectrum of epithelial neoplasms induced by sorafenib.
Kwon EJ; Kish LS; Jaworsky C
J Am Acad Dermatol; 2009 Sep; 61(3):522-7. PubMed ID: 19700018
[TBL] [Abstract][Full Text] [Related]
9. Multiple squamous cell carcinomas of the skin after therapy with sorafenib combined with tipifarnib.
Hong DS; Reddy SB; Prieto VG; Wright JJ; Tannir NM; Cohen PR; Diwan AH; Evans HL; Kurzrock R
Arch Dermatol; 2008 Jun; 144(6):779-82. PubMed ID: 18559769
[TBL] [Abstract][Full Text] [Related]
10. Sorafenib-induced eruptive melanocytic lesions.
Kong HH; Sibaud V; Chanco Turner ML; Fojo T; Hornyak TJ; Chevreau C
Arch Dermatol; 2008 Jun; 144(6):820-2. PubMed ID: 18559790
[No Abstract] [Full Text] [Related]
11. Follicular hyperplasia on the face subsequent to therapy with sorafenib. A new skin side effect.
Lopez V; Pinazo I; Marti N; Monteagudo C; Jorda E
J Eur Acad Dermatol Venereol; 2009 Aug; 23(8):959-60. PubMed ID: 18785888
[No Abstract] [Full Text] [Related]
12. Sorafenib-induced psoriasiform eruption in a patient with metastatic thyroid carcinoma.
Diamantis ML; Chon SY
J Drugs Dermatol; 2010 Feb; 9(2):169-71. PubMed ID: 20214183
[TBL] [Abstract][Full Text] [Related]
13. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma.
Ratain MJ; Eisen T; Stadler WM; Flaherty KT; Kaye SB; Rosner GL; Gore M; Desai AA; Patnaik A; Xiong HQ; Rowinsky E; Abbruzzese JL; Xia C; Simantov R; Schwartz B; O'Dwyer PJ
J Clin Oncol; 2006 Jun; 24(16):2505-12. PubMed ID: 16636341
[TBL] [Abstract][Full Text] [Related]
14. Rapid response to sorafenib in metastatic medullary thyroid carcinoma.
Frank-Raue K; Ganten M; Kreissl MC; Raue F
Exp Clin Endocrinol Diabetes; 2011 Mar; 119(3):151-5. PubMed ID: 20827665
[TBL] [Abstract][Full Text] [Related]
15. Eruptive keratoacanthoma-type squamous cell carcinomas in patients taking sorafenib for the treatment of solid tumors.
Smith KJ; Haley H; Hamza S; Skelton HG
Dermatol Surg; 2009 Nov; 35(11):1766-70. PubMed ID: 19660024
[TBL] [Abstract][Full Text] [Related]
16. Sorafenib-induced erythema multiforme in metastatic renal cell carcinoma.
Bilaç C; Müezzinoğlu T; Ermertcan AT; Kayhan TC; Temeltaş G; Oztürkcan S; Temiz P
Cutan Ocul Toxicol; 2009; 28(2):90-2. PubMed ID: 19514932
[TBL] [Abstract][Full Text] [Related]
17. Safety and feasibility of using sorafenib in recurrent hepatocellular carcinoma after orthotopic liver transplantation.
Kim R; El-Gazzaz G; Tan A; Elson P; Byrne M; Chang YD; Aucejo F
Oncology; 2010; 79(1-2):62-6. PubMed ID: 21071991
[TBL] [Abstract][Full Text] [Related]
18. Sorafenib-induced hepatic encephalopathy.
Marks AB; Gerard R; Fournier P; Coupe P; Gautier S
Ann Pharmacother; 2009 Dec; 43(12):2121. PubMed ID: 19861429
[No Abstract] [Full Text] [Related]
19. Sorafenib-induced palmoplantar hyperkeratosis.
Lountzis NI; Maroon MS
J Drugs Dermatol; 2008 Jun; 7(6):588-9. PubMed ID: 18561593
[TBL] [Abstract][Full Text] [Related]
20. Sorafenib and surgical complications: a case report of adverse reaction to sorafenib during treatment for renal cell carcinoma.
Eng FC; Easson AM; Szentgyorgyi E; Knox JJ
Eur J Surg Oncol; 2009 Feb; 35(2):219-21. PubMed ID: 17976949
[No Abstract] [Full Text] [Related]
[Next] [New Search]
